Abstract
Donor lymphocyte infusion has been used in the management of relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. It can eradicate minimal residual disease or be used to rescue a hematologic relapse, being able to induce durable remissions in a subset of patients. With the increased use of haploidentical hematopoietic cell transplantation, there is renewed interest in the use of donor lymphocytes to either treat or prevent disease relapse post transplant. Published retrospective and small prospective studies have shown encouraging results with therapeutic donor lymphocyte infusion in different haploidentical transplantation platforms. In this consensus paper, finalized on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarize the available evidence on the use of donor lymphocyte infusion from haploidentical donor, and provide recommendations on its therapeutic, pre-emptive and prophylactic use in clinical practice. © 2020 Ferrata Storti Foundation
Original language | English |
---|---|
Pages (from-to) | 47-58 |
Number of pages | 12 |
Journal | Haematologica |
Volume | 105 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2020 |
Keywords
- granulocyte colony stimulating factor
- HLA antigen
- acute leukemia
- acute lymphoblastic leukemia
- bone marrow aplasia
- bone marrow transplantation
- chemotherapy
- chimera
- chronic graft versus host disease
- clinical practice
- disease free survival
- donor lymphocyte infusion
- follow up
- haploidentical donor
- hematopoietic stem cell transplantation
- human
- immunosuppressive treatment
- minimal residual disease
- mortality
- mutation
- overall survival
- peripheral blood stem cell
- prophylaxis
- Review
- risk factor